MedTrace Logo

Regulatory BCells in Systemic Lupus Erythematosus

NCT03178721 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-06-07

No results posted yet for this study

Summary

Systemic lupus erythematosus , the archetypal multisystem autoimmune disease, presents many diagnostic and management challenges. One such challenge is the excess cardiovascular disease observed in patients with Systemic lupus erythematosus . Coronary heart disease and other manifestations of atherosclerosis continue to be a major cause of death in patients with Systemic lupus erythematosus.Regulatory B-cells have been identified as a negative regulator of the immune system that inhibit pathological immune response by suppressing both uncontrolled protective immune response and damaging autoimmune responses

Conditions

Interventions

DIAGNOSTIC_TEST

blood sample

study B regulatory in blood and its correlation with atherosclerosis

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-25
Primary Completion
2018-06-25
Completion
2018-07-25

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03178721 on ClinicalTrials.gov